Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (AVHHL) Inventory (2019 - 2025)

Historic Inventory for AVITA Medical (AVHHL) over the last 7 years, with Q4 2025 value amounting to $6.9 million.

  • AVITA Medical's Inventory fell 471.87% to $6.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.9 million, marking a year-over-year decrease of 471.87%. This contributed to the annual value of $6.9 million for FY2025, which is 471.87% down from last year.
  • According to the latest figures from Q4 2025, AVITA Medical's Inventory is $6.9 million, which was down 471.87% from $7.2 million recorded in Q3 2025.
  • In the past 5 years, AVITA Medical's Inventory ranged from a high of $8.4 million in Q1 2025 and a low of $1.6 million during Q2 2021
  • In the last 5 years, AVITA Medical's Inventory had a median value of $3.7 million in 2023 and averaged $4.4 million.
  • Per our database at Business Quant, AVITA Medical's Inventory crashed by 685.89% in 2021 and then surged by 16334.12% in 2023.
  • Over the past 5 years, AVITA Medical's Inventory (Quarter) stood at $2.1 million in 2021, then fell by 0.33% to $2.1 million in 2022, then skyrocketed by 163.34% to $5.6 million in 2023, then rose by 29.9% to $7.3 million in 2024, then fell by 4.72% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q4 2025, $7.2 million for Q3 2025, and $7.5 million during Q2 2025.